100 related articles for article (PubMed ID: 10822100)
1. Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine.
Liao M; Lu Y; Xiao Y; Dierich MP; Chen Y
Peptides; 2000 Apr; 21(4):463-8. PubMed ID: 10822100
[TBL] [Abstract][Full Text] [Related]
2. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
Dong XN; Xiao Y; Chen YH
Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
[TBL] [Abstract][Full Text] [Related]
3. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody.
Xiao Y; Zhao Y; Lu Y; Chen YH
Immunol Invest; 2000 Feb; 29(1):41-50. PubMed ID: 10709845
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
[TBL] [Abstract][Full Text] [Related]
5. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
6. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
[TBL] [Abstract][Full Text] [Related]
7. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
Xiao Y; Dong X; Chen Y
Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
[TBL] [Abstract][Full Text] [Related]
8. Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine.
Xiao Y; Dong XN; Chen YH
Hybridoma; 2000 Aug; 19(4):347-50. PubMed ID: 11001409
[TBL] [Abstract][Full Text] [Related]
9. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
Yu T; Bai Y; Dierich MP; Chen YH
Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
[TBL] [Abstract][Full Text] [Related]
10. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.
Zhang G; Chen YH
Immunobiology; 2003; 207(4):259-64. PubMed ID: 12952348
[TBL] [Abstract][Full Text] [Related]
11. The recombinant immunogen with high-density epitopes of ELDKWA and ELDEWA induced antibodies recognizing both epitopes on HIV-1 gp41.
Wang Z; Liu Z; Cheng X; Chen YH
Microbiol Immunol; 2005; 49(8):703-9. PubMed ID: 16113499
[TBL] [Abstract][Full Text] [Related]
12. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes.
Lapelosa M; Gallicchio E; Arnold GF; Arnold E; Levy RM
J Mol Biol; 2009 Jan; 385(2):675-91. PubMed ID: 19026659
[TBL] [Abstract][Full Text] [Related]
13. A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.
Huang J; Dong X; Liu Z; Qin L; Chen YH
Immunol Lett; 2002 Dec; 84(3):205-9. PubMed ID: 12413738
[TBL] [Abstract][Full Text] [Related]
14. HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies.
Tian H; Xiao Y; Zhu M; Chen YH
Int Immunopharmacol; 2001 Apr; 1(4):763-8. PubMed ID: 11357888
[TBL] [Abstract][Full Text] [Related]
15. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1.
Ding J; Lu Y; Chen Y
FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and specificity of the candidate multi-epitope-vaccines against HIV-1.
Lu Y; Ding J; Chen YH
Immunopharmacol Immunotoxicol; 2001 Nov; 23(4):487-94. PubMed ID: 11792008
[TBL] [Abstract][Full Text] [Related]
17. Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1.
Li H; Liu ZQ; Ding J; Chen YH
Immunol Lett; 2002 Nov; 84(2):153-7. PubMed ID: 12270553
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of alpha -helicity in the HIV-1 inhibitory peptide DP178 leads to an increased affinity for human monoclonal antibody 2F5 but does not elicit neutralizing responses in vitro. Implications for vaccine design.
Joyce JG; Hurni WM; Bogusky MJ; Garsky VM; Liang X; Citron MP; Danzeisen RC; Miller MD; Shiver JW; Keller PM
J Biol Chem; 2002 Nov; 277(48):45811-20. PubMed ID: 12237296
[TBL] [Abstract][Full Text] [Related]
19. Structure-affinity relationships in the gp41 ELDKWA epitope for the HIV-1 neutralizing monoclonal antibody 2F5: effects of side-chain and backbone modifications and conformational constraints.
Tian Y; Ramesh CV; Ma X; Naqvi S; Patel T; Cenizal T; Tiscione M; Diaz K; Crea T; Arnold E; Arnold GF; Taylor JW
J Pept Res; 2002 Jun; 59(6):264-76. PubMed ID: 12010517
[TBL] [Abstract][Full Text] [Related]
20. Induction of monoclonal antibodies with predefined epitope-specificity by epitope-vaccines.
Tian H; Xiao Y; Zhu M; Dierich MP; Chen YH
Immunol Lett; 2001 Jan; 75(2):161-2. PubMed ID: 11137143
[No Abstract] [Full Text] [Related]
[Next] [New Search]